Edition:
United States

Eli Lilly and Co (LLY.F)

LLY.F on Frankfurt Stock Exchange

70.63EUR
27 Sep 2016
Change (% chg)

€-1.68 (-2.33%)
Prev Close
€72.31
Open
€70.63
Day's High
€70.63
Day's Low
€70.63
Volume
--
Avg. Vol
1,029
52-wk High
€81.91
52-wk Low
€60.60

Select another date:

Tue, Sep 20 2016

Regeneron, Teva take aim at Lilly/Pfizer pain drug

Sept 20 Regeneron Pharmaceuticals Inc and Israeli drugmaker Teva Pharmaceutical Industries on Tuesday said they would co-develop Regeneron's experimental new type of pain drug and together market the medicine if it succeeds in trials and is approved.

BRIEF-EMA recommends approval of three new cancer treatments

* Recommends approval of Eli Lilly and Boehringer Ingelheim's Glyxambi for treatment of type 2 diabetes

BRIEF-Levi Garraway to become senior vice president of global oncology at Lilly

* Levi garraway, m.d., ph.d., to become senior vice president of global oncology at lilly, succeeding richard gaynor, m.d., who is retiring after a distinguished career

BRIEF-Lilly-Health Canada approves new indication for Jardiance tablets

* Health Canada approves new indication for Jardiance (empagliflozin) tablets for adults with type 2 diabetes and established cardiovascular disease Source text for Eikon: Further company coverage:

BRIEF-Eli Lilly names Joshua Smiley senior VP, finance, and treasurer effective Oct 1

* Eli lilly and co says joshua smiley will be appointed to senior vice president, finance, and treasurer effective october 1 Source text for Eikon: Further company coverage:

Lilly breast cancer drug stumbles, but trial continues

U.S. drugmaker Eli Lilly and Co on Wednesday said it would continue a late-stage trial of its experimental breast cancer drug in combination with a widely used treatment even though an independent panel determined the combination therapy failed to meet its interim effectiveness goal.

Panel recommends Lilly continue breast cancer drug study

Aug 10 Eli Lilly and Co said an interim analysis of a late-stage study testing its breast cancer drug abemaciclib by an independent panel showed the treatment did not meet the effectiveness criteria and recommended that the company continue the trial.

BRIEF-Express Scripts adds Lilly's Taltz psoriasis drug to its excluded medicines list

Aug 1 Express Scripts : * says adds Eli Lilly's new Taltz psoriasis drug to its list of excluded medications, making it ineligible for coverage.

U.S. probes contracts between Eli Lilly and PBMs

Eli Lilly and Co said it received a civil investigative demand from the U.S. attorney's office for the southern district of New York, requesting documents and information relating to contracts with pharmacy benefit managers (PBMs).

Eli Lilly says authorities seek documents on PBM contracts

July 28 Eli Lilly and Co said it received a civil investigative demand from the U.S. attorney's office for the southern district of New York, requesting documents and information relating to contracts with pharmacy benefit managers.

Select another date: